Analyst Research

Report Title Price
Provider: Sadif Analytics Prime
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mauna Kea Technologies receives regulatory approval for Cellvizio in Japan


Monday, 28 Apr 2014 02:42am EDT 

Mauna Kea Technologies SA:Received regulatory approval in Japan for Cellvizio flagship product.Approval by Japan's Ministry of Health, Labor and Welfare (MHLW) includes Class 1 authorization for Cellvizio technology as well as Class 2 designation, known as NINSHO approval, covering use of Cellvizio probes in endoscopic use.The approval applies to all current Cellvizio indications including gastrointestinal, urologic, and respiratory.At Fujita Health University, medical center in Chubu region, Cellvizio is already shared by multiples departments, including Gastroenterology and Hepatology, Interventional Pulmonology and Urology.